Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin.
about
Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patientsVenous thromboembolic diseaseHeparin-induced thrombocytopenia: an updateGuidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolismDiagnosis and management of heparin-induced thrombocytopenia.Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparinHeparin-induced thrombocytopenia from venous thromboembolism treatment.Treatment of heparin-induced thrombocytopenia in cardiovascular patients.Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin?Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.Anticoagulation strategies for treatment of ischemic stroke and antiphospholipid syndrome: case report and review of the literature.Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options.Beyond heparin and warfarin: the new generation of anticoagulants.Heparin-induced thrombocytopenia: treatment options and special considerations.Fondaparinux as a treatment option for heparin-induced thrombocytopenia.Latest medical treatment strategies for venous thromboembolism.Successful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia type II (HIT II): a case seriesCerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis.Successful use of argatroban during the third trimester of pregnancy: case report and review of the literature.Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues.Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.Fondaparinux: does it cause HIT? Can it treat HIT?Heparin-induced thrombocytopenia: evaluation of IgG and IgGAM ELISA assays.IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics.Fondaparinux (Arixtra(R)), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia?HIT paradigms and paradoxes.Successful Use of Alternative Anticoagulants in the Management of Heparin-induced Thrombocytopenia with Thrombotic Complications: Report of 5 cases and review of literature.Fondaparinux-associated heparin-induced thrombocytopeniaParenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesThe Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4.Efficacy and safety of off-label use of fondaparinux in the management of heparin-induced thrombocytopenia with thrombosis in an elderly woman.Intravenous warfarin and heparin-induced thrombocytopenia: making the diagnosis, management, modern monitoring, and multidisciplinary care.Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study.Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment.
P2860
Q24200589-D196CE57-E565-4E13-8717-4536157A7A20Q24631121-C0A4F311-6D3E-4916-B85E-08DF7876176CQ24815767-AF749A38-6299-498A-96B9-ECEB98A09E14Q28079081-D9F99406-13AE-4903-8D28-0C7C2B1D6CA1Q33365985-F8BA7D8A-E6D5-4270-A5E4-2AC34717DEABQ33367978-0D987C90-2257-4D6D-882C-9D19D3FC2816Q33369355-C859BE95-AD22-4A08-80F8-64C09B4EF685Q33370137-B304B96D-B578-4184-96FD-86F8538357E6Q33370224-FBD8965F-9764-4367-B550-E42339447A00Q33370696-B956A0B1-70D3-412F-938D-56E4A392AF32Q33371628-8499A505-B497-4070-9779-EDC38266F86FQ33372266-9B116589-D010-4F3A-8528-6532F9ED2021Q33372751-8C540C17-5414-4DDD-8FE9-2C0BE6ED8ED6Q33373128-A0A9FD3A-0FDA-438F-B8EB-B8CB37971A0EQ33374258-1C0D0BD6-904B-49E0-B6AC-C8013EF4C58EQ33374658-1890A261-E6BC-4D88-80CB-FE6713C7FE74Q33375448-F4FA64A2-929B-4BE2-9882-D37AD77FD156Q33375535-D26CD96A-16C4-4374-9F4D-39C256CD7B30Q33380179-7B16E372-8FE1-455C-B540-D24AA3CD3775Q33380621-0118821F-0E37-4B72-85CD-609632FF90C5Q33382099-EA7674B9-2344-46F4-A835-0374068A2CFBQ33386145-448D9F20-F088-479D-9AD9-9B1E9923B449Q33386621-6C4832A8-158B-4FE6-82E7-A838A5393E3AQ33389966-E998EB37-8D59-457E-A0F4-46B9CB1743E7Q33392864-DFF39030-1C31-4A48-ADA4-E46195EC7D17Q33393048-B6EE8F16-D50B-4583-8933-AFC1F613C725Q33393788-A328A4DE-0389-45A4-9884-AB232FEB3527Q33394988-D5D0919C-4FD1-4201-9CCE-63901EF6B3DEQ33396313-4B74037B-7400-4C26-AF73-905C377BA74FQ33398271-3826B527-152F-439F-A77A-65F8F2050B5AQ33399335-A0D65442-9EEF-4274-9E63-EAA51B5E804FQ33399576-82A3EBA8-EC9A-470F-8DFC-AFF040B56E13Q33401236-46033C12-5FA4-4824-A88D-D2E157FE2667Q33406904-C6AA50BA-A4E0-49BF-A947-403850743090Q33407198-99CDE932-0E26-47F4-B000-3F397285AD22Q33407740-33273E57-37A3-4860-890D-1692B4BBB347Q33408949-7421C1F4-E0B8-45FE-AB7E-3EE422A32978Q33411642-3FEF928E-D371-4AC7-9C67-D3749ED5E5CBQ33416315-BE899956-4266-4875-AA87-A2C40BB7D4E1Q33420446-0497D9CD-D358-499F-88D5-863FAC516F85
P2860
Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Effect of fondaparinux on plat ...... y with unfractionated heparin.
@ast
Effect of fondaparinux on plat ...... y with unfractionated heparin.
@en
type
label
Effect of fondaparinux on plat ...... y with unfractionated heparin.
@ast
Effect of fondaparinux on plat ...... y with unfractionated heparin.
@en
prefLabel
Effect of fondaparinux on plat ...... y with unfractionated heparin.
@ast
Effect of fondaparinux on plat ...... y with unfractionated heparin.
@en
P2093
P1433
P1476
Effect of fondaparinux on plat ...... y with unfractionated heparin.
@en
P2093
Beng H Chong
Dick Meuleman
Jean-Marc Herbert
Jean-Pascal Herault
John G Kelton
Maurice Petitou
Petra Eichler
Pierre Savi
Roger Cariou
Yves Gruel
P304
P356
10.1182/BLOOD-2004-05-2010
P407
P577
2004-09-23T00:00:00Z